China Universal Asset Management Co. Ltd. Grows Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

China Universal Asset Management Co. Ltd. lifted its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 62.9% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,364 shares of the biopharmaceutical company’s stock after buying an additional 9,411 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Halozyme Therapeutics were worth $1,395,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its stake in shares of Halozyme Therapeutics by 32.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,495 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 1,358 shares in the last quarter. Arbor Investment Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at $1,027,000. State of Alaska Department of Revenue lifted its stake in shares of Halozyme Therapeutics by 7.2% during the 3rd quarter. State of Alaska Department of Revenue now owns 14,838 shares of the biopharmaceutical company’s stock valued at $849,000 after buying an additional 995 shares in the last quarter. Boston Trust Walden Corp increased its holdings in Halozyme Therapeutics by 54.0% in the 3rd quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock valued at $39,073,000 after acquiring an additional 239,321 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Halozyme Therapeutics by 20.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,582 shares of the biopharmaceutical company’s stock valued at $261,000 after acquiring an additional 782 shares during the last quarter. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $50.46 on Tuesday. The company has a 50 day moving average price of $57.99 and a 200-day moving average price of $51.67. Halozyme Therapeutics, Inc. has a fifty-two week low of $33.07 and a fifty-two week high of $65.53. The stock has a market capitalization of $6.42 billion, a PE ratio of 20.85, a PEG ratio of 0.50 and a beta of 1.27. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The firm had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. During the same quarter in the prior year, the company earned $0.68 EPS. The company’s revenue was up 4.7% compared to the same quarter last year. Equities analysts predict that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $58.00 to $62.00 in a report on Monday, October 7th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and boosted their target price for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Morgan Stanley boosted their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, HC Wainwright restated a “buy” rating and issued a $65.00 target price on shares of Halozyme Therapeutics in a report on Friday. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $60.44.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $59.20, for a total value of $592,000.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Matthew L. Posard sold 9,881 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the transaction, the director now owns 69,874 shares in the company, valued at $4,031,729.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Helen Torley sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $59.20, for a total transaction of $592,000.00. Following the transaction, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $40,063,244.80. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 89,881 shares of company stock valued at $5,169,834. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.